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7,12-DIMETHYLBENz(a)ANTHRACENE (DMBA) given in a single dose (30 mg.).
in oil by stomach tube or intravenously (5 mg.) in lipid emulsion induces mam-
marytumours inSprague-Dawley ratswithin 2-3 months (Huggins, Briziarelli and
Sutton, 1959; Huggins, Grand andBrillantes, 1961), and also causes severe adrenal
necrosis within 2-3 days (Huggins and Morii, 1961). We have shown that DMBA
itself is probably not responsible for adrenal necrosis (Wheatley, Kernohan and
Currie, 1966; Wheatley, Hamilton, Currie, Boyland and Sims, 1966) but must
first be metabolized by the liver. Boyland and Sims (1965) found that DMBA is
metabolized by rat liver mainly by hydroxylation of the methyl groups; 7-
hydroxymethyl-12-methylbenz(a)anthracene is probably the adrenocorticolytic
metabolite (Boyland, Sims and Huggins, 1965; Wheatley, Hamilton, Currie,
Boyland and Sims, 1966). Boyland et al. (1965) tested the carcinogenicity of
DMBA and its hydroxymethyl derivatives in rats and mice. Briefly, the 7-
hydroxymethyl derivative induced mammary tumours but with a longer mean
induction time than DMBA whereas the 12-hydroxymethyl derivative was not
carcinogenic in rats although it was in mice.
It is also possible that a metabolite ofDMBA, and not DMBA itself, is respon-
sible for tumour induction. We have therefore tested the ability of DMBA ta
produce tumours in rats with impaired liver function.
MATERIALS AND METHODS
Sprague-Dawley female rats from an accredited stock were obtained from
Oxford Laboratory Animal Colonies, Oxford, England. CC14 (AnalaR) was given
to 60 rats at a dose of 0 3 ml. of a 50% solution in olive oil intraperitoneally.
Forty-three rats were partially hepatectomized, two-thirds of the liver being
removed by the method of Higgins and Anderson (1931). Forty rats were given
olive oil intraperitoneally (013 ml.) as controls. Twenty-four hours later the
ratsreceived 5 mg. DMBA in 1V0 ml. 15% cottonseed oil emulsion via a lateral tail
vein. At the time of DMBA injection rats were 50 days old and weighed about
150 g.
The severity of the combined treatments resulted in a high early mortality.
The surviving rats were palpated twice a week from the fourth week afterinjection.
Tumours were measured and charted as described previously (Stevens, Stevens and
Currie, 1965). The experiment was terminated at 6 months and an assessment
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was made of tumour types from their growth curves and histological appearances
as described by Stevens et al., 1965.
RESULTS
Rats with impaired liver function at the time ofDMBA administration did not
differ from intact healthy control rats in the percentage ofrats developing tumours
or in the tumour induction period (Table 1). The incidence of rats bearing
TABLE I.-Mammary Tumours in Rats Given DMBA After Liver Interfrence
Number of rats with Total Average number tumours/ Mean induction
Group tumours tumours tumour-bearing rat time (weeks)
Control . 19/25 . 39 . 2-05 . 15-3
CCl4 . 25/29 . 64 . 2-56 . 15-1
Partial . 17/24 . 36 . 212 . 15-9
hepatectomy
mammary tumours 6 months after DMBA treatment varied between 70 and 86
per cent. (Fig. 1). This is lower than reported by others (e.g. Huggins, Grand and
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FIG. 1.-Percentage ofmammary tumour-bearing ratsagainst time after treatment ofSprague-Dawley
female rats with 5 mg. DMBA intravenously.
- control rats
* - CCI4-treated rats
- -- partially hepatectomized rats
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were palpated during life which proved on histological examination to be simple
cysts. Table 1 also records the average number of tumours developing per rat.
Although the rats pretreated with carbon tetrachloride developed more tumours
than rats in the other two groups, the difference was not significant.
TABLE II.-Growth Characteristic8 of Mammary Tumour8 in Rats
Given DMBA After Liver Interference
Unclassified
Total number (found at
Group of tumours Growing Static Regressing* necropsy)
Control . 39 . 13 . 12 9 . 5
CCd4 . 64 . 26 . 24 9 . 5
Partial . 36 . 14 . 5 . 11 . 6
hepatectomy
* In each group, 3 " tumours " are included which showed complete regression. Whilst they were
almost undoubtedly mammary tumours, histological confirmation was not obtained.
The growth characteristics of the tumours are summarized in Table II. A
greater proportion of tumours were either growing or regressing in the partial
hepatectomy group, but with the small numbers involved no significant difference
from controls was found.
Histologically, tumours in the partially hepatectomized rats and in the CC14-
treated rats were of similar types to those found in the control group.
DISCUSSION
Impairment of liver function at the time of administration of DMBA does not
appreciably alter the incidence of Sprague-Dawley rats developing mammarv
tumours. If DMBA is metabolized to a powerful carcinogenic derivative, control
rats would be expected to produce more tumours than the experimental groups,
but this is not so. Since the metabolism ofDMBA is considerably affected by the
treatments employed in this experiment, rats will presumably be exposed to
unaltered DMBA for longer than controls. An increased yield of tumours might
be expected if DMBA itself is the potent carcinogen; a slightly higher yield was
found in CCl4-treated rats but in partially hepatectomized rats there was a slightly
lower yield than controls; however, these differences are not significant. This
suggests that DMBA itselfis the primary carcinogenic agent and not a metabolite.
Furthermore, since rats capable of efficiently metabolizing DMBA (control group)
yielded overall a similar number of tumours to rats which could not metabolize
DMBA so quickly, carcinogenesis must be initiated very early after the injection
of the polycyclic hydrocarbon. This is in agreement with the findings of Dao,
Tanaka and Gawlak (1964) who showed that mammary glands transplanted to
untreated rats as soon as 6 hours after injection of DMBA developed tumours.
It is considered that a certain amount of DMBA is absorbed by the quiescent
mammary tissue soon after injection, and that the metabolism of the bulk of the
remaining DMBA by the liver does not significantly influence tumour production.
Tanaka and Dao (1965) investigated the effect of a very small dose of CC14
(insufficient to protect rats from adrenal necrosis following DMBA treatment) on
mammary tumours after 20 mg. DMBA intragastrically. Apart from perhaps a
longer induction time, they report no other effect.
216LIVER INTERFERENCE AND DMBA TUMOUR INDUCTION 217
In another related study Helfenstein and Young (1963) investigated the effect
of metyrapone (2-methyl-1,2-bis-(3-pyridyl)-1-propanone). Whilst this drug
protected adrenal glands from the adrenocorticolytic action of DMBA, little
difference in mammary tumour production was found between metyrapone-
treated and control rats.
It can be concluded that the carcinogenic nature and the adrenocorticolytic
action of DMBA are essentially unrelated phenomena. These experiments
suggest that DMBA is the potent carcinogen and not a metabolite.
SUMMARY
Liver function was impaired in Sprague-Dawley female rats by carbon tetra-
chloride treatment or by partial hepatectomy 24 hours before treatment with
5 mg. 7,12-dimethylbenz(a)anthracene intravenously. Although these treat-
ments are known to protect the adrenal glands by preventing the metabolism of
DMBA to an active adrenocorticolytic derivative, they did not affect the incidence
of rats developing mammary tumours or the relative frequencies of the tumours
of different growth characteristics to any significant extent.
It is concluded that DMBA itself, and not a derivative, is probably responsible
for mammary tumour induction.
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